ObsEva Announce s Relationship with Syneos Health to Commercialize Linzagolix
-Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of uterine fibroids-
– Financing agreement with JGB Management to fund the planned launch of linzagolix as well as other development and operational expense s –
– Amendment of Kissei exclusive license and supply agreement –
Ad hoc announcement pursuant to Art.
Read the source article at Stock Market Quotes and News